Suppr超能文献

神经介素U受体2选择性肽激动剂对小鼠食欲和催乳素分泌的抑制作用

Suppressive Effects of Neuromedin U Receptor 2-Selective Peptide Agonists on Appetite and Prolactin Secretion in Mice.

作者信息

Nomoto Asuka, Suzuki Yui, Morito Katsuya, Nagasawa Kazuki, Takayama Kentaro

机构信息

Laboratory of Environmental Biochemistry, Kyoto Pharmaceutical University, 5 Misasaginakauchi-cho, Yamashina, Kyoto 607-8414, Japan.

出版信息

ACS Med Chem Lett. 2024 Feb 14;15(3):376-380. doi: 10.1021/acsmedchemlett.3c00541. eCollection 2024 Mar 14.

Abstract

Neuromedin U receptor 2 (NMUR2), which is expressed in the central nervous system (CNS) including the hypothalamus, has been noted as a therapeutic target against obesity. We previously reported that intranasal administration of CPN-219, a NMUR2-selective hexapeptide agonist, suppresses body weight gain in mice; however, there is no detailed information regarding its CNS effects. Recently, in addition to appetite suppression, stress responses and regulation of prolactin (PRL) secretion have also attracted attention. NMUR2 expressed in the hypothalamic tuberoinfundibular dopaminergic neurons has emerged as an alternative target for treating hyperprolactinemia. Here, CPN-219 decreased food intake up to 24 h after administration at a dose of 200 nmol, resulting in body weight gain suppression, although grooming and anxiety-like behaviors were transiently induced. Interestingly, the restraint stress-induced increase in plasma PRL levels was significantly suppressed at a lower dose of 20 nmol, indicating the potential for drug development as an anti-PRL agent of NMUR2-selective agonists.

摘要

神经介素U受体2(NMUR2)在下丘脑等中枢神经系统(CNS)中表达,已被视为对抗肥胖的治疗靶点。我们之前报道过,鼻内给予NMUR2选择性六肽激动剂CPN - 219可抑制小鼠体重增加;然而,关于其对中枢神经系统的影响尚无详细信息。最近,除了食欲抑制外,应激反应和催乳素(PRL)分泌的调节也受到了关注。在下丘脑结节漏斗多巴胺能神经元中表达的NMUR2已成为治疗高催乳素血症的另一个靶点。在此,CPN - 219在剂量为200 nmol时给药后24小时内可减少食物摄入量,导致体重增加受到抑制,尽管梳理毛发和焦虑样行为会被短暂诱导。有趣的是,在较低剂量20 nmol时,束缚应激诱导的血浆PRL水平升高被显著抑制,这表明NMUR2选择性激动剂作为抗PRL药物具有药物开发潜力。

相似文献

1
Suppressive Effects of Neuromedin U Receptor 2-Selective Peptide Agonists on Appetite and Prolactin Secretion in Mice.
ACS Med Chem Lett. 2024 Feb 14;15(3):376-380. doi: 10.1021/acsmedchemlett.3c00541. eCollection 2024 Mar 14.
2
Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice.
Int J Obes (Lond). 2017 Dec;41(12):1790-1797. doi: 10.1038/ijo.2017.176. Epub 2017 Jul 31.
3
Small-Molecule Neuromedin U Receptor 2 Agonists Suppress Food Intake and Decrease Visceral Fat in Animal Models.
Pharmacol Res Perspect. 2018 Aug 23;6(5):e00425. doi: 10.1002/prp2.425. eCollection 2018 Oct.
6
A chemically stable peptide agonist to neuromedin U receptor type 2.
Bioorg Med Chem. 2020 May 15;28(10):115454. doi: 10.1016/j.bmc.2020.115454. Epub 2020 Mar 22.
7
Neuromedin U receptor 2-deficient mice display differential responses in sensory perception, stress, and feeding.
Mol Cell Biol. 2006 Dec;26(24):9352-63. doi: 10.1128/MCB.01148-06. Epub 2006 Oct 9.
8
Transnasal Delivery of the Peptide Agonist Specific to Neuromedin-U Receptor 2 to the Brain for the Treatment of Obesity.
Mol Pharm. 2020 Jan 6;17(1):32-39. doi: 10.1021/acs.molpharmaceut.9b00571. Epub 2019 Dec 9.
9
Prolactin regulation of tuberoinfundibular dopaminergic neurons: immunoneutralization studies.
Brain Res. 2000 Jan 3;852(1):28-36. doi: 10.1016/s0006-8993(99)02182-4.

引用本文的文献

本文引用的文献

1
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association.
Circulation. 2021 May 25;143(21):e984-e1010. doi: 10.1161/CIR.0000000000000973. Epub 2021 Apr 22.
2
A chemically stable peptide agonist to neuromedin U receptor type 2.
Bioorg Med Chem. 2020 May 15;28(10):115454. doi: 10.1016/j.bmc.2020.115454. Epub 2020 Mar 22.
3
Effects of neuromedin U-8 on stress responsiveness and hypothalamus-pituitary-adrenal axis activity in male C57BL/6J mice.
Horm Behav. 2020 May;121:104666. doi: 10.1016/j.yhbeh.2019.104666. Epub 2020 Mar 2.
4
Neuromedin U suppresses prolactin secretion via dopamine neurons of the arcuate nucleus.
Biochem Biophys Res Commun. 2020 Jan 8;521(2):521-526. doi: 10.1016/j.bbrc.2019.10.156. Epub 2019 Oct 31.
5
Rapid transport of insulin to the brain following intranasal administration in rats.
Neural Regen Res. 2019 Jun;14(6):1046-1051. doi: 10.4103/1673-5374.250624.
6
Differential effects of selective agonists of neuromedin U1 and U2 receptors in obese and diabetic mice.
Br J Pharmacol. 2018 Jan;175(2):359-373. doi: 10.1111/bph.14077. Epub 2017 Dec 18.
7
Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice.
Int J Obes (Lond). 2017 Dec;41(12):1790-1797. doi: 10.1038/ijo.2017.176. Epub 2017 Jul 31.
8
Potent Body Weight-Lowering Effect of a Neuromedin U Receptor 2-selective PEGylated Peptide.
J Med Chem. 2017 Jul 27;60(14):6089-6097. doi: 10.1021/acs.jmedchem.7b00330. Epub 2017 Jul 18.
9
Discovery of a Human Neuromedin U Receptor 1-Selective Hexapeptide Agonist with Enhanced Serum Stability.
J Med Chem. 2017 Jun 22;60(12):5228-5234. doi: 10.1021/acs.jmedchem.7b00694. Epub 2017 Jun 2.
10
A PEGylated analog of short-length Neuromedin U with potent anorectic and anti-obesity effects.
Bioorg Med Chem. 2017 Apr 15;25(8):2307-2312. doi: 10.1016/j.bmc.2017.02.023. Epub 2017 Feb 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验